LY01008 vs Zirabev (bevacizumab-bvzr)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

LY01008

Marketed by Luye Pharma Group

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03533127 · Phase 3 · status unknown

This was a randomized, double-blind, active-controlled equivalence trial in 648 patients that measured objective tumor response rate, using the same paclitaxel/carboplatin backbone in both arms. LY01008's response rate was statistically equivalent to bevacizumab's, within the prespecified margin, meeting the trial's own equivalence criterion.

Reported efficacy

Best Objective Response Rate (19 weeks from randomization): LY01008 vs Avastin (bevacizumab) + paclitaxel/carboplatin, first-line non-squamous NSCLC: ORR 48.5% vs 53.0%; stratified ORR ratio 0.91 (90% CI 0.80-1.04), within prespecified equivalence margin 0.75-1.33 -> equivalence/non-inferiority demonstrated. (met)

Result source: NCT03533127

Zirabev (bevacizumab-bvzr)

Marketed by Pfizer

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT02364999 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 719 participants, using tumor response by RECIST as its primary clinical endpoint. PF-06439535 had a confirmed response rate of 45.3% versus 44.6% with European bevacizumab, and the prespecified equivalence margins were met, supporting a strong evidence grade.

Reported efficacy

Objective Response Rate (ORR) by Week 19 (25 weeks): Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89) (met)

Result source: NCT02364999

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLY01008Zirabev (bevacizumab-bvzr)
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported45.3% vs 44.6%vs Bevacizumab-EUwk 25 · n 358NCT02364999
Duration of response, median—Not reported8.4 vs 6.6vs Bevacizumab-EUn 162NCT02364999

PFS, median

LY01008
—Not reported
Zirabev (bevacizumab-bvzr)
—Not reported

OS, median

LY01008
—Not reported
Zirabev (bevacizumab-bvzr)
—Not reported

ORR

LY01008
—Not reported
Zirabev (bevacizumab-bvzr)
45.3% vs 44.6%vs Bevacizumab-EUwk 25 · n 358NCT02364999

Duration of response, median

LY01008
—Not reported
Zirabev (bevacizumab-bvzr)
8.4 vs 6.6vs Bevacizumab-EUn 162NCT02364999
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

LY01008
LY01008 vs Avastin (bevacizumab) + paclitaxel/carboplatin, first-line non-squamous NSCLC: ORR 48.5% vs 53.0%; stratified ORR ratio 0.91 (90% CI 0.80-1.04), within prespecified equivalence margin 0.75-1.33 -> equivalence/non-inferiority demonstrated. NCT03533127 · Phase 3 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. LY01008: 0 of 4 rows · Zirabev (bevacizumab-bvzr): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricZirabev (bevacizumab-bvzr)
Dropout rate
46.1%
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
—
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Serious AEs
22.8%
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
alopecia 46.6%
anaemia 28.7%
fatigue 20.5%
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Zirabev (bevacizumab-bvzr)

ORR 45.3% (n=358) vs 44.6% (n=361) Bevacizumab-EU @ 25wk
responder rate · % of participants
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Duration of Response 8.38 vs 6.62 Bevacizumab-EU months
time to event · months
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 · converted to months from 36.3 weeks as posted
PFS 32.3% (n=358) vs 30.5% (n=361) Bevacizumab-EU @ 55wk
responder rate · % of participants
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Overall Survival 65.8% (n=358) vs 64.1% (n=361) Bevacizumab-EU @ 55wk
responder rate · % of participants
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY01008's landscape · Zirabev (bevacizumab-bvzr)'s landscape